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Introduction {#acr211148-sec-0005}
============

As the novel COVID‐19 became a pandemic, there were early signs that people who were older, had a greater number of health conditions, or had immunodeficiencies would be at greater risk of contracting it and/or having more severe disease [1](#acr211148-bib-0001){ref-type="ref"}, [2](#acr211148-bib-0002){ref-type="ref"}. Patients with rheumatic diseases are known to be at higher risk of infection because of immune dysregulation, comorbidities, and immune‐modulating treatments [3](#acr211148-bib-0003){ref-type="ref"}, [4](#acr211148-bib-0004){ref-type="ref"}, [5](#acr211148-bib-0005){ref-type="ref"}. Many of these diseases (eg, rheumatoid arthritis \[RA\]) affect patients of an older age on average [6](#acr211148-bib-0006){ref-type="ref"}. Beyond the typical challenges of self‐managing a chronic disease, disease management has become significantly more complex with the implementation of social distancing, including limiting nonessential health care visits. This has led to confusion about how patients with rheumatic diseases should balance managing their disease and reducing their risk of infection [7](#acr211148-bib-0007){ref-type="ref"}, [8](#acr211148-bib-0008){ref-type="ref"}.

In addition, there were early reports that treatments typically used for rheumatic diseases might be effective against COVID‐19 [9](#acr211148-bib-0009){ref-type="ref"}. Most notably, in vitro studies and a small cohort study reported that hydroxychloroquine (HCQ) showed some benefits in treating COVID‐19 [10](#acr211148-bib-0010){ref-type="ref"}, [11](#acr211148-bib-0011){ref-type="ref"}, [12](#acr211148-bib-0012){ref-type="ref"}. HCQ is a commonly used conventional disease‐modifying antirheumatic drug (DMARD) that reduces flares and mortality in systemic lupus erythematosus and is a common treatment for RA and other rheumatic diseases, In a small case‐series, the interleukin‐6 (IL‐6) inhibitor tocilizumab, a biologic DMARD, also showed promise for treating respiratory manifestations related to COVID‐19 [13](#acr211148-bib-0013){ref-type="ref"}. There are several ongoing clinical trials examining the use of tocilizumab or sarilumab as treatment for COVID‐19 [14](#acr211148-bib-0014){ref-type="ref"}. These early reports and the emergency authorization by the Food and Drug Administration (FDA) of HCQ as a treatment for COVID‐19 have led to critical shortages in medication availability during a time when regular access to medication is inherently more difficult [15](#acr211148-bib-0015){ref-type="ref"}.

The objective of this study was to understand how patients with rheumatic and musculoskeletal diseases in the United States have been impacted by the COVID‐19 pandemic through a one‐time COVID‐19 questionnaire querying their experiences during the last 2 weeks of March 2020.

Patients and Methods {#acr211148-sec-0006}
====================

The study population consisted of participants in FORWARD, The National Databank for Rheumatic Diseases, a longitudinal open‐enrollment observational patient registry [16](#acr211148-bib-0016){ref-type="ref"}. Participants are volunteers recruited primarily by US rheumatologists to complete comprehensive, semiannual questionnaires online, by mail, or by telephone interview. Participants included in this analysis responded to an online supplemental COVID‐19 questionnaire focused on their experiences around COVID‐19 symptoms, testing, and medication access in the 2 weeks prior to questionnaire completion. The supplemental COVID‐19 questionnaire was sent via an e‐mail link on March 25, 2020, to all FORWARD participants who had been invited to complete the current semiannual questionnaire. Responses to the supplemental questionnaire were collected between March 25 and April 1, 2020. In order to be included in this study, participants must have previously completed a semiannual questionnaire within the last 2 years. This study was approved by the Via Christi Hospitals Wichita, Inc., Institutional Review Board (IRB00001674), and all participants consented to participate.

 {#acr211148-sec-0007}

### Study variables {#acr211148-sec-0008}

#### COVID‐19 questionnaire {#acr211148-sec-0009}

Participants were asked about their rheumatic disease activity, development of any new symptoms (fever, cough, sore throat, shortness of breath, fatigue, muscle pain, headache, gastrointestinal symptoms, chest pain, abdominal pain, loss/change in taste or smell, and anxiety), testing for COVID‐19, and any changes in their rheumatology treatment plan in the previous 2 weeks (See [Appendix](#acr211148-sup-0001){ref-type="supplementary-material"} for full list of items). Participants were given the opportunity to share free‐response comments about their experiences during the COVID‐19 pandemic.

#### Semiannual questionnaire {#acr211148-sec-0010}

The most recently completed semiannual questionnaire was linked to each participant\'s COVID‐19 questionnaire. The following were assessed: demographics, including age, sex, race, education level, marital status, urban/rural area, history of smoking, body mass index, and health insurance status; primary rheumatic disease diagnosis; patient‐reported outcome measures, including pain, global severity, fatigue, Health Assessment Questionnaire II (HAQ‐II) score (a validated measure of physical function) [17](#acr211148-bib-0017){ref-type="ref"}, and Patient Activity Scale II \[PAS‐II\] score (a validated measure of disease activity) [18](#acr211148-bib-0018){ref-type="ref"}, [19](#acr211148-bib-0019){ref-type="ref"}; comorbid conditions, including heart disease, pulmonary disease, diabetes, renal disease, and liver disease; and medication use, including DMARDs, corticosteroids, and nonsteroidal anti‐inflammatory drugs.

### Screening criteria {#acr211148-sec-0011}

Screening criteria were applied to supplemental COVID‐19 questionnaire respondents based on March 20, 2020, CDC recommendations for SARS‐CoV‐2 testing priority [20](#acr211148-bib-0020){ref-type="ref"} and included 1) fever, 2) at least one symptom of acute respiratory illness (new cough, dyspnea, sore throat, chest pain, or loss of taste/smell within the prior 2 weeks), and 3) at least one of the following: is 65 or more years old, is in a long‐term care facility, has an autoimmune diagnosis, has a Rheumatic Disease Comorbidity Index (RDCI) [21](#acr211148-bib-0021){ref-type="ref"} of at least 2, or is a health care worker/first responder.

### Quantitative analysis {#acr211148-sec-0012}

Differences between COVID‐19 questionnaire respondents and nonrespondents were assessed with Student\'s *t* tests for continuous variables and χ^2^ tests for categorical variables. Responses to all COVID‐19 items were tabulated, and significance was assessed with χ^2^ tests. All tests were two‐tailed, and *P* values less than 0.05 were considered significant. Logistic regression modeled the association between disease activity and reported cancelation or postponement of appointments, with all sociodemographic information, RDCI, diagnosis, and number of rheumatology and general practitioner visits as covariables. Data were analyzed using Stata version 14.2 [22](#acr211148-bib-0022){ref-type="ref"}.

### Qualitative analysis {#acr211148-sec-0013}

Two of the authors (YS and TAS) independently read and open coded the free‐text comments using a grounded theory approach [23](#acr211148-bib-0023){ref-type="ref"}, [24](#acr211148-bib-0024){ref-type="ref"}, [25](#acr211148-bib-0025){ref-type="ref"}. They met to discuss their coding and notes and organized them into themes.

### Figure creation {#acr211148-sec-0014}

UpSetR version 1.4 was used to generate the UpSet plot [26](#acr211148-bib-0026){ref-type="ref"}. [Wordclouds.com](https://www.Wordclouds.com) was used to generate the word cloud, using the cloud graphic from Font Awesome version 5.13 as a template. The relative size of each word represents the frequency with which it appeared in the free‐response comments.

Results {#acr211148-sec-0015}
=======

A total of 7061 active FORWARD participants were sent the supplemental COVID‐19 questionnaire. Of those, 530 participants responded during the first 7 days used for this report. RA was the most frequent diagnosis (61%). Geographic distribution was diverse, with respondents representing 49 of 50 states (15% of respondents were from the Northeast, 31% were from the Midwest, 27% were from the South, and 25% were from the West). Compared with nonrespondents, respondents were more likely to be white, to have more education, to have completed their semiannual questionnaire online rather than on paper or by interview, and to have lower disease activity (Table [1](#acr211148-tbl-0001){ref-type="table"}).

###### 

Characteristics of participants with rheumatic diseases who were sent the COVID‐19 supplemental questionnaire by response status

  Characteristics                     Respondents (n = 530)   Nonrespondents (n = 6531)   *P*
  ----------------------------------- ----------------------- --------------------------- -------------
  Demographics                                                                             
  Age, mean (SD), y                   65.0 (10.9)             64.2 (12.5)                 0.14
  Female, %                           84.4                    84.2                        0.92
  White, %                            93.5                    90.2                        **0.02**
  Education, mean (SD), y             15.3 (1.9)              14.9 (2.2)                  **\<0.001**
  Married, %                          71.1                    67.1                        0.06
  Rural, %                            19.8                    22.5                        0.15
  History of smoking, %               36.8                    41.0                        0.06
  BMI, mean (SD), kg/m^2^             28.1 (7.5)              29.0 (7.9)                  **0.01**
  Health insurance, %                 98.9                    99.0                        0.79
  US geographic distribution, %                                                            
  Northeast                           14.9                    18.2                        **\<0.01**
  Midwest                             30.8                    32.3                        **\<0.01**
  South                               27.0                    27.3                        **\<0.01**
  West                                24.7                    17.8                        **\<0.01**
  Semiannual questionnaire                                                                 
  Online, %                           85.8                    55.5                        **\<0.001**
  Paper, %                            14.2                    39.6                        **\<0.001**
  Interview, %                        0                       4.9                         **\<0.001**
  Time since completion, d            211 (92)                312 (195)                   **\<0.001**
  Patient‐Reported Outcome Measures                                                       
  Pain (0‐10), mean (SD)              3.1 (2.6)               3.9 (2.7)                   **\<0.001**
  Global severity (0‐10), mean (SD)   3.0 (2.3)               3.7 (2.6)                   **\<0.001**
  Fatigue (0‐10), mean (SD)           3.5 (2.9)               4.3 (3.0)                   **\<0.001**
  HAQ‐II (0‐3), mean (SD)             0.75 (0.61)             0.91 (0.67)                 **\<0.001**
  PAS‐II (0‐3), mean (SD)             2.8 (2.1)               3.5 (2.2)                   **\<0.001**
  Primary diagnosis, %                                                                     
  Rheumatoid arthritis                60.6                    62.1                        0.34
  Osteoarthritis                      11.1                    12.8                        0.34
  Systemic lupus erythematosus        5.7                     5.1                         ...
  Other                               22.6                    20.0                        0.34
  Comorbid conditions, %                                                                  0.34
  Heart disease                       22.1                    22.9                        0.65
  Pulmonary disease                   32.3                    31.3                        0.63
  Diabetes                            11.7                    14.4                        0.09
  Renal disease                       14.3                    14.3                        0.96
  Liver disease                       9.4                     8.1                         0.28
  Medications, %                                                                           
  Conventional DMARD                  52.6                    46.9                        **0.01**
  Hydroxychloroquine                  17.7                    19.5                        0.31
  Biologic DMARD                      39.0                    37.1                        0.37
  IL‐6 inhibitor                      3.2                     3.8                         0.49
  JAK inhibitor                       7.0                     5.1                         0.07
  Corticosteroid                      18.1                    18.6                        0.79
  NSAID                               38.8                    35.3                        0.10

Bold value indicates *P* \< 0.05.

Abbreviation: BMI, body mass index; DMARD, disease‐modifying antirheumatic drug; HAQ‐II, Health Assessment Questionnaire II; IL‐6, interleukin 6; JAK, Janus kinase; NSAID, nonsteroidal anti‐inflammatory drug; PAS‐II, Patient Activity Scale II.

John Wiley & Sons, Ltd

 {#acr211148-sec-0016}

### Symptoms, screening criteria, and SARS‐CoV‐2 testing {#acr211148-sec-0017}

Approximately half of respondents reported experiencing new symptoms potentially associated with COVID‐19 in the 2 weeks prior to questionnaire completion. The most frequently reported new symptoms were fatigue (18%), anxiety (16%), headache (13%), muscle pain (12%), and cough (10%) (Table [2](#acr211148-tbl-0002){ref-type="table"}). Of the 530 respondents, 11 (2%) met COVID‐19 screening criteria. Of those 11, two respondents had sought testing and, despite one of them reporting exposure to a confirmed case, neither received it. In addition, six others who did not meet the screening criteria reported an attempt to get tested for COVID‐19, and three received testing. None tested positive for SARS‐CoV‐2 (Figure [1](#acr211148-fig-0001){ref-type="fig"}).

###### 

Frequency of new symptoms[^a^](#acr211148-note-0006){ref-type="fn"}

  Symptom                               Participants Reporting, %
  ------------------------------------- ---------------------------
  Fever                                 2.8
  Cough                                 9.9
  Sore throat                           8.5
  Shortness of breath                   4.1
  Tiredness (fatigue)                   17.9
  Muscle pain                           11.6
  Headache                              13.0
  Diarrhea, vomiting, or nausea         5.7
  Chest pain                            2.4
  Pain or discomfort in upper abdomen   2.6
  Pain or discomfort in lower abdomen   3.7
  Loss/change in taste or smell         1.6
  Nervousness (anxiety)                 16.2
  None of these                         58.4

Participants were asked if they had experienced any new symptoms in the 2 weeks prior to questionnaire completion; they selected from a provided list of symptoms related to COVID‐19.

John Wiley & Sons, Ltd

![UpSet plot summarizing risk factors, symptoms, and testing experiences for each participant who met screening criteria and/or attempted to get tested for severe acute respiratory syndrome coronavirus 2. Each vertical line represents an individual participant, and each solid circle indicates that the participant reported that new symptom or testing experience or has the specified risk factor. All participants who received a test tested negative. No respondents were in a long‐term care facility. Exposure indicates that the participant reported known exposure to a COVID‐19--positive patient. Nonautoimmune diagnoses in this cohort are osteoarthritis and fibromyalgia. RDCI, Rheumatic Disease Comorbidity Index.](ACR2-2-335-g001){#acr211148-fig-0001}

### Changes in rheumatology care {#acr211148-sec-0018}

Of the 530 COVID‐19 questionnaire respondents, 471 answered questions about changes in their rheumatology care. Of these, 197 respondents (42%) reported some change to their care in the previous 2 weeks. Of the 197, 48% reported canceled or postponed appointments, 24% switched to teleconference appointments, 14% reported self‐imposed changes to their medication list or dose, 11% reported physician‐directed changes to their medication list or dose, 10% were unable to obtain their medication, and 4% were unable to reach their rheumatology office. Respondents with higher disease activity were more likely to report canceled or postponed appointments, even after controlling for demographics, comorbidities, and frequency of rheumatology/general practitioner appointments in the past (odds ratio 2.4 \[95% confidence interval 1.3‐4.6\]; *P* \< 0.01). Respondents who reported experiencing new symptoms associated with COVID‐19 in the last 2 weeks were more likely to have had medications added or removed by their physician (Table [3](#acr211148-tbl-0003){ref-type="table"}).

###### 

Reported changes in rheumatology care caused by COVID‐19 in the previous 2 weeks by prior disease activity and new symptoms[^a^](#acr211148-note-0007){ref-type="fn"}

  Change in Care                                           All (N = 471), %   Disease Activity[^b^](#acr211148-note-0008){ref-type="fn"}   New Symptoms              
  -------------------------------------------------------- ------------------ ------------------------------------------------------------ -------------- ---------- ----------
  Canceled or postponed appointments                       20.8               **16.6**                                                     **31.3**       18.3       23.8
  Switched to teleconference appointments                  10.6               7.9                                                          14.8           10.9       10.3
  Could not reach the rheumatology office                  1.5                0.3                                                          2.3            **0**      **3.3**
  Could not obtain my medications                          4.2                2.4                                                          7.0            4.3        4.2
  Physician changed the dose of patient\'s medication(s)   2.5                2.1                                                          3.9            1.6        3.7
  Physician added or removed medication(s)                 2.5                1.4                                                          4.7            **0.4**    **5.1**
  Patient changed the dose of my medication(s)             1.5                1.4                                                          1.6            1.6        1.4
  Patient added or removed medication(s)                   4.7                5.5                                                          4.7            3.9        5.6
  Other                                                    7.4                7.9                                                          7.0            6.6        8.4
  No change                                                58.2               **62.8**                                                     **50.2**       **63.0**   **52.3**

Statistically significant differences are shown in bold.

Disease activity was defined by Patient Activity Scale II (PAS‐II), with a PAS‐II score of 3.7 or less as low disease activity and a PAS‐II score of more than 3.7 as high disease activity [27](#acr211148-bib-0027){ref-type="ref"}.

John Wiley & Sons, Ltd

### Patient experiences {#acr211148-sec-0019}

The qualitative analysis identified the following four major themes from 211 respondents' free‐response comments: emotions in response to COVID‐19‐related experiences, perceptions of risk, protective measures to reduce risk of COVID‐19 infection, and impacts on rheumatic disease treatment and access to care, including medications and rheumatology consultations (Table [4](#acr211148-tbl-0004){ref-type="table"} and Figure [2](#acr211148-fig-0002){ref-type="fig"}).

###### 

Illustrative quotes for each major theme identified in respondents' free‐response comments

  Theme                                                                                     Example Quote
  ----------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Emotions in response to COVID‐19--related experiences                                      
  Anxiety/nervousness/worry/fear                                                            "I am not normally a nervous person but thinking of contracting this virus really scares me. I lived, barely, through a H1N1 virus attack of my system 5 years ago but this is a brand new virus and it really makes me nervous."
  Desire to reduce risk of COVID‐19                                                         "I am taking the threat of the virus seriously. I am self isolating and having my groceries and medications delivered."
  Not worried about COVID‐19                                                                "I am not worried about COVID19 and think the entire thing is overblown."
  Uncertainty                                                                               "I started with dry cough, nasal drip with no congestion at all. Then shortness of breath two days later, low grade fever. Headache, severe fatigue, muscle aches in arms and legs, sore throat that comes and goes. Developed pneumonia around 10 days in. While I tested negative for COVID‐19 this is suspect because I never get sick and I haven\'t had pneumonia since childhood (once). I work from home and have no reason to have acquired pneumonia."
  Frustration                                                                               "Unable to get name brand plaquenil due to covid 19 virus usage. They don\'t seem to care about people that need the drug for immune diseases."
  Sadness                                                                                   "I miss my grandbabies. I watched one 3 days a week. I cried myself to sleep missing them except for the last 3 days finally. My daughter sends pics. Working on video chat situations."
  Gratefulness                                                                              "I am so grateful that my family understands my health issues and is staying away."
  Hope                                                                                      "I am hopeful we will escape this pestilence! and I hope you will, too."
  Wanting to help                                                                           "I flew back home from \[State A\] via \[City 1\] to \[City 2\], \[State B\] on March 19th. I was exhausted for two days after traveling during which time I had a lowgrade fever and a headache. On the third day, I developed a bad cough with a tightness in my chest that last for about a week. About the sixth day, I called my primary doctor who recommended the hot tea and normal things of comfort. I had started to feel a bit better by then. I really didn\'t want to use testing supplies when I was keeping myself in quarantine since I arrived home from \[State A\] anyway."
  Managing negative emotions/stress                                                         "The stress of the pandemic has affected my immune system. It\'s like a domino effect. I started with sores in my mouth, then in my ear, which triggered the polychondritis, which causes pain and pressure on the left side of my head, which makes me fatigued more than usual, which frustrates me and makes me depressed and triggers the fibromyalgia and colitis. During isolation I must focus harder to find those things I can do, instead of focusing on those I can\'t. There is still joy to be found."
  Perceptions of risk                                                                        
  Increased risk due to age, chronic conditions, or potential exposure to infected people   "I have put my \[biologic\] on hold, with the concurrence of my rheumatologist. This is because my husband is a clinician who has likely exposure at his hospital; we live in \[city\], where COVID‐19 is present."
  Increased risk due to taking immunosuppressive medications                                "I think my RA is more active over past 3‐4 months since I decreased dose of Methotrexate from 7 to 6 tabs 2.5mg/week in Dec2019. I am afraid to increase it due to Covid 19."
  Personal limit for acceptable/unacceptable risk                                           "I work in healthcare and I plan to go off my immuno‐suppressants if I am exposed. I plan to stay home if we get a case of COVID‐19 where I work. I go to work; I come home. Don\'t go to the stores. We have 21 cases in my county."
  Protective measures to reduce COVID‐19 infection                                           
  Self‐isolation/social distancing                                                          "Because \[State\] has not placed a quarantine or shelter‐in‐place directive asking only for social distancing, I am still taking my walks and trying to avoid all the people who never came and now use the area for a touch of nature. Some of the trails are narrow and it\'s difficult to get the entire 6' off to the side. However in general, people are respecting the 6' whenever possible. I continue to grocery shop taking advantage of senior hours whenever possible, wearing gloves, making my own alcohol wipes when picking up items and cleaning the gloves before removing them etc."
  Canceling medical appointments that can be postponed                                      "I cancelled my cardiologist appointment because of covid‐19 fears. I\'m debating on whether to keep my doctors appoints I have for next month."
  Working from home                                                                         "I had to strongly advocate for myself at work to protect myself. I have completely switched all work activities to telemedicine and am working 100% from home with the support of my division."
  Canceling travel plans                                                                    "I had plans to return to my home in \[State\] within the next two weeks. I am not sure if I will as \[State\] has the highest incidences of Covid‐19. I live Upstate but there have been many cases present there and testing is restricted."
  Wearing masks or gloves when in close contact with others                                 "Shopping in the grocery store is very dangerous right now. I wear a mask but people do not social distance. There are no available wipes for carriages, very unhealthy using payment devices when hand sanitizer is not available after touching buttons for pin \#..."
  Impacts on treatment and access to care                                                    
  Stopping DMARDs to lessen risk of COVID‐19                                                "Stopped taking Leflunomide ‐ concerned about immunosuppressive effect"
  Medical appointments canceled or switched to telephone or video consultations             "I do have an appointment with my primary care doctor for a regular checkup next Monday and that has been switched from an in‐person visit to a telephone appointment at their request. An online video appointment was also available but we decided a phone call would be best."
  Unavailability of medications (especially hydroxychloroquine)                             "I tried to get one extra refill on my hydroxychloroquine, after Trump lied about it being useful for cv‐19, because I could see that would cause a run on the drug. I was denied the refill by my pharmacy provider, \[pharmacy name\], because it was not yet due for refill. After reading that the AHIP was urging companies to allow an extra refill for necessary maintenance medications, I wrote an enote to \[pharmacy name\] asking them to reconsider their denial and send me the medication now so that I have it to assure continuity of my treatment plan in the future. I have yet to hear back from them."
  Loss of health care coverage                                                              "I may lose health care coverage within the next 30 days due to economic changes during this crisis. This may severely affect my rheumatology care."

Abbreviation: DMARD, disease‐modifying antirheumatic drug.
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![Word cloud demonstrating the top themes and most frequently seen words in respondents' free‐response comments.](ACR2-2-335-g002){#acr211148-fig-0002}

#### Emotions in response to COVID‐19‐related experiences {#acr211148-sec-0020}

The most commonly reported emotions were anxiety, nervousness, worry, and fear. Respondents worried about being infected and developing COVID‐19, whether they would survive an infection, how their medications would affect their risk, and the impact of the pandemic on access to medications and health care. Some noted that the anxiety/stress seemed to worsen their arthritis symptoms. In response to the threat of COVID‐19, most respondents reported a desire to reduce their risk and take actions to protect themselves. Only a small minority of participants expressed a lack of worry toward COVID‐19.

Respondents also reported feeling uncertain about whether to stop taking their medications as well as whether their symptoms were due to COVID‐19 or another condition, such as allergies. They felt frustrated when confronted with difficulties in accessing medication or obtaining permission to work from home. Practicing social distancing caused feelings of sadness and loneliness in respondents who could no longer see family and friends in person.

A few commenters expressed positive emotions such as feeling grateful (eg, for the support of family or colleagues), hopeful, or wanting to help. One person did not want to get tested for COVID‐19 despite having symptoms consistent with COVID‐19 because they had quarantined at home since getting sick and did not want to waste scarce testing supplies. Some acknowledged the need to manage negative emotions and stress.

#### Perceptions of risk {#acr211148-sec-0021}

Many participants expressed beliefs about their increased risk of infection/severe outcomes due to COVID‐19 related to older age, chronic conditions, or exposure through the workplace or contact with family members. Many thought that use of immunosuppressive medications increased their risk/potential severity of COVID‐19 and that stopping such medications could reduce their risk. This belief seemed to stem from previous experiences of being instructed to stop immunosuppressive medications during infections or before surgeries. A minority thought that taking HCQ might lower their risk of developing COVID‐19. Some commenters described setting personal limits for acceptable/unacceptable risk, such as planning to stop going to work once COVID‐19 cases emerged at their workplace.

#### Protective measures to reduce risk {#acr211148-sec-0022}

The majority of respondents described adoption of self‐isolation and social distancing measures, often in response to state shelter‐in‐place orders. They reported actions such as stopping in‐person contact with family and friends, staying at home except to buy groceries and go to medical appointments, having groceries and meals delivered, canceling all but the most critical medical appointments, and canceling travel plans. Some participants were able to arrange working from home, but others (mostly health care workers) could not. Several also discussed wearing masks or using gloves when they needed to go to a grocery store or pharmacy, but that other shoppers did not always respect the recommended distance of 6 feet. Adapting physical activity routines to adhere to social distancing could be challenging because some participants were accustomed to exercising in an indoor public space or with friends. Walking or running outside, sometimes with a pet, was reported as a common alternative activity.

#### Impacts on treatment and access to care {#acr211148-sec-0023}

As discussed above, some participants reported stopping their DMARD use to lessen their risk of infection, sometimes with the approval of their rheumatologist. Others continued to take their medications as usual. Many reported having medical appointments canceled or switched to telephone or video consultations. Infusions were still received as scheduled by most respondents. Availability of medications, particularly HCQ, was a frequent concern, and some people reported being unable to obtain refills from their pharmacy. Some attributed the shortage of HCQ to widespread misinformation that this medication was proven to be an effective treatment for COVID‐19. One person reported concern over losing health care coverage (and as a result, access to rheumatology care) because of the economic impact of COVID‐19.

Discussion {#acr211148-sec-0024}
==========

In this study, we report how patients with rheumatic and musculoskeletal diseases throughout the United States were impacted by the COVID‐19 pandemic during the latter half of March 2020, the relatively early days of government‐imposed isolation decrees. Although none of the respondents tested positive for COVID‐19, many were already affected by it. One‐fifth of respondents reported postponed or canceled medical appointments, and half reported new symptoms associated with COVID‐19. Our qualitative analysis of participant comments found four themes that highlighted the impact of COVID‐19 on mental health, perceptions that immunosuppressive medications increase the risk of COVID‐19 infection, uncertainty about whether arthritis medications should be continued during the COVID‐19 outbreak, and challenges in accessing HCQ, which has drawn attention as a potential treatment for COVID‐19.

Many respondents were not sure if they should stop their medications---additional evidence‐based guidance is needed in this area for patients and rheumatologists. Recent editorials are recommending not modifying treatment unless symptoms of COVID‐19 manifest [7](#acr211148-bib-0007){ref-type="ref"}, [28](#acr211148-bib-0028){ref-type="ref"}. It is important for clinicians to be aware that some patients have stopped taking their medications without a recommendation from a health professional.

Respondents with higher disease activity were more likely to have canceled/postponed appointments even after adjustment for several important confounders such as comorbidities and frequency of clinical appointments; it is unclear if this decision was made by the participant or physician because less controlled disease often comes with greater infection risk. Further study is needed to understand how lack of appointments for those likely more in need of health care follow‐up may impact patients' health. Similarly, patients reporting new symptoms were less likely to have been able to reach their rheumatology clinic and were more likely to have had their physician change their medications; new symptoms likely led patients to contact their physicians, leading to these findings.

Initial reports suggesting HCQ as an effective COVID‐19 treatment [11](#acr211148-bib-0011){ref-type="ref"}, [29](#acr211148-bib-0029){ref-type="ref"} have come under increased scrutiny because of questionable methodologies and conclusions [30](#acr211148-bib-0030){ref-type="ref"}, [31](#acr211148-bib-0031){ref-type="ref"}. The unconfirmed reports of HCQ as a viable treatment option for COVID‐19, along with FDA emergency authorization for use in cases of hospitalization and the resulting shortage/refusal by pharmacies to refill prescriptions, is a major issue for patients and the rheumatology community [32](#acr211148-bib-0032){ref-type="ref"}, [33](#acr211148-bib-0033){ref-type="ref"}. Although additional studies launch to examine this in greater detail, there is a need to raise awareness that HCQ is not yet a proven treatment or prophylactic for COVID‐19 and is a critical medication for many patients with rheumatic diseases and reduces mortality and flares in patients with lupus [34](#acr211148-bib-0034){ref-type="ref"}. As one participant wrote, "I have taken Plaquenil for over 20 years and cannot get any now as it\'s being used as a possible treatment for Covid19. \[...\] I feel close to hopeless."

Our study has some important limitations. With a single e‐mail as the basis of our initial questionnaire, there was possible bias toward participants with greater socioeconomic status, fewer symptoms, and lower disease activity. We accounted for this difference by comparing respondents with nonrespondents who had completed their semiannual questionnaire. Future work should also examine the impact on more vulnerable populations, ie, those with lower socioeconomic status or lower education and/or those from racial/ethnic minorities. It is also likely that study participants who were diagnosed with COVID‐19 or hospitalized were not able to respond during this short time period. It is important to note that because this cohort is composed entirely of patients with rheumatic diseases, our ability to differentiate between results that are specific to the rheumatology community and those that are likely to be the case throughout the population is limited. Lastly, comments were not required of participants, and our qualitative analysis was inherently biased toward those who found the need to add additional detail on their experiences beyond our questionnaire.

In summary, we found that after 2 weeks, many participants in the United States with rheumatic diseases already had important changes to their health care, including canceling appointments, which was independently linked to increased disease activity, and altering medications without professional consultation or because of hydroxychloroquine shortage. There were important impacts on mental health and continued uncertainty on how best to treat these diseases and stay protected from COVID‐19. Participants who met priority screening criteria for SARS‐CoV‐2 testing were not tested, those who were tested did not meet screening criteria, and none tested positive. We have planned follow‐up questionnaires with similar questions and the ability to modify them as guidelines change and as participants report testing positive for COVID‐19. As evidence accumulates on the effectiveness of potential COVID‐19 treatments, many of which are used in treating rheumatic diseases, effort is needed to ensure continued access to treatments that have already been proven effective for rheumatic diseases.
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